Verrica Pharmaceuticals Inc
VRCA7.820USD
-0.290-3.58%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
74.21MMarket Cap
LossP/E TTM
More Details of Verrica Pharmaceuticals Inc Company
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).
Verrica Pharmaceuticals Inc Info
Ticker SymbolVRCA
Company nameVerrica Pharmaceuticals Inc
IPO dateJun 15, 2018
CEORieger (Jayson)
Number of employees71
Security typeOrdinary Share
Fiscal year-endJun 15
Address44 West Gay Street
CityWEST CHESTER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19380
Phone14844533300
Websitehttps://verrica.com/
Ticker SymbolVRCA
IPO dateJun 15, 2018
CEORieger (Jayson)
Company Executives of Verrica Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Jayson Rieger
Dr. Jayson Rieger
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
183.30K
+105.98%
Mr. David Zawitz
Mr. David Zawitz
Chief Operating Officer
Chief Operating Officer
21.00K
+90.91%
Dr. Noah L. Rosenberg, M.D.
Dr. Noah L. Rosenberg, M.D.
Chief Medical Officer
Chief Medical Officer
2.36K
--
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00
--
Dr. Gavin Corcoran
Dr. Gavin Corcoran
Independent Director
Independent Director
2.00
--
Dr. Lawrence Eichenfield, M.D.
Dr. Lawrence Eichenfield, M.D.
Independent Director
Independent Director
--
--
Mr. John J. Kirby
Mr. John J. Kirby
Interim Chief Financial Officer, Interim Principal Financial Officer
Interim Chief Financial Officer, Interim Principal Financial Officer
--
--
Mr. Paul B. Manning
Mr. Paul B. Manning
Chairman of the Board
Chairman of the Board
--
--
Mr. Mark A. Prygocki, Sr.
Mr. Mark A. Prygocki, Sr.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Jayson Rieger
Dr. Jayson Rieger
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
183.30K
+105.98%
Mr. David Zawitz
Mr. David Zawitz
Chief Operating Officer
Chief Operating Officer
21.00K
+90.91%
Dr. Noah L. Rosenberg, M.D.
Dr. Noah L. Rosenberg, M.D.
Chief Medical Officer
Chief Medical Officer
2.36K
--
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00
--
Dr. Gavin Corcoran
Dr. Gavin Corcoran
Independent Director
Independent Director
2.00
--
Dr. Lawrence Eichenfield, M.D.
Dr. Lawrence Eichenfield, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Dec 5
Updated: Fri, Dec 5
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Manning (Paul B.)
28.51%
BKB Growth Investments LLC
20.94%
Caligan Partners, LP
5.78%
Affinity Asset Advisors LLC
4.42%
Armistice Capital LLC
4.00%
Other
36.35%
Shareholders
Shareholders
Proportion
Manning (Paul B.)
28.51%
BKB Growth Investments LLC
20.94%
Caligan Partners, LP
5.78%
Affinity Asset Advisors LLC
4.42%
Armistice Capital LLC
4.00%
Other
36.35%
Shareholder Types
Shareholders
Proportion
Individual Investor
31.41%
Corporation
21.10%
Hedge Fund
14.84%
Investment Advisor
2.60%
Investment Advisor/Hedge Fund
2.43%
Venture Capital
0.18%
Research Firm
0.02%
Other
27.43%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
171
2.46M
26.06%
-1.46M
2025Q2
183
8.91M
96.35%
+3.15M
2025Q1
194
69.94M
75.99%
+19.16M
2024Q4
191
70.39M
77.72%
+35.42M
2024Q3
179
29.67M
67.28%
-5.27M
2024Q2
173
33.68M
79.75%
-1.13M
2024Q1
171
34.51M
82.01%
-2.46M
2023Q4
170
35.04M
83.66%
+1.56M
2023Q3
172
32.74M
78.91%
-2.85M
2023Q2
169
31.35M
77.69%
+2.98M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Manning (Paul B.)
4.98M
52.73%
+3.12M
+167.58%
Nov 26, 2024
BKB Growth Investments LLC
597.61K
6.33%
+597.61K
--
Nov 22, 2024
Caligan Partners, LP
923.91K
9.78%
+24.62K
+2.74%
Jun 30, 2025
Armistice Capital LLC
888.13K
9.4%
+31.39K
+3.66%
Jun 30, 2025
The Vanguard Group, Inc.
216.83K
2.3%
-19.30K
-8.17%
Jun 30, 2025
Stalfort (John A)
187.38K
1.98%
+23.81K
+14.56%
Apr 01, 2025
Rieger (Jayson)
88.99K
0.94%
+30.02K
+50.90%
Apr 01, 2025
Sovran Advisors LLC
75.04K
0.79%
+35.82K
+91.35%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Russell 2000 Growth ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
Dimensional US Core Equity 1 ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
Avantis US Small Cap Equity ETF
0%
ProShares UltraPro Russell2000
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 ETF
0%
View more
iShares Micro-Cap ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Global X Russell 2000 ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 23, 2025
Merger
10→1
Date
Type
Ratio
Jul 23, 2025
Merger
10→1
FAQs
Who are the top five shareholders of Verrica Pharmaceuticals Inc?
The top five shareholders of Verrica Pharmaceuticals Inc are:
Manning (Paul B.) holds 4.98M shares, accounting for 52.73% of the total shares.
BKB Growth Investments LLC holds 597.61K shares, accounting for 6.33% of the total shares.
Caligan Partners, LP holds 923.91K shares, accounting for 9.78% of the total shares.
Armistice Capital LLC holds 888.13K shares, accounting for 9.40% of the total shares.
The Vanguard Group, Inc. holds 216.83K shares, accounting for 2.30% of the total shares.
Manning (Paul B.) holds 4.98M shares, accounting for 52.73% of the total shares.
BKB Growth Investments LLC holds 597.61K shares, accounting for 6.33% of the total shares.
Caligan Partners, LP holds 923.91K shares, accounting for 9.78% of the total shares.
Armistice Capital LLC holds 888.13K shares, accounting for 9.40% of the total shares.
The Vanguard Group, Inc. holds 216.83K shares, accounting for 2.30% of the total shares.
What are the top three shareholder types of Verrica Pharmaceuticals Inc?
The top three shareholder types of Verrica Pharmaceuticals Inc are:
Manning (Paul B.)
BKB Growth Investments LLC
Caligan Partners, LP
Manning (Paul B.)
BKB Growth Investments LLC
Caligan Partners, LP
How many institutions hold shares of Verrica Pharmaceuticals Inc (VRCA)?
As of 2025Q3, 171 institutions hold shares of Verrica Pharmaceuticals Inc, with a combined market value of approximately 2.46M, accounting for 26.06% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -70.28%.
What is the biggest source of revenue for Verrica Pharmaceuticals Inc?
In --, the -- business generated the highest revenue for Verrica Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
